Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Takeda reveals promising phase 3 results for oveporexton, a potential breakthrough treatment for narcolepsy type 1, targeting excessive daytime sleepiness.

Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies

Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits. 

Late-Breaking Phase 2b PARADIGM Data Support Continued Development of PrimeC in ALS

Videos

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]

Centering Empathy in Parkinson Care by Listening Beyond the Diagnosis: María L. De León, MD

Here's some of what is coming soon to NeurologyLive® this week. 

This Week on NeurologyLive® — July 14, 2025

The associate professor of medicine at the Icahn School of Medicine at Mount Sinai outlined emerging interventions aimed at enhancing glymphatic clearance to potentially lower Alzheimer disease risk. [WATCH TIME: 4 minutes]

Exploring Tools to Target the Glymphatic System and Alzheimer Disease Risk: Andrew Varga, MD

Movement disorder specialist and patient living with Parkinson disease.

Associate professor, Ferkauf Graduate School of Psychology, Yeshiva University, and associate professor, department of neurology, Albert Einstein College of Medicine.

The professor of neurology at Albert Einstein College of Medicine talked about new findings presented at AHS, which suggested that both men and women with migraine can face significantly increased risks of ischemic stroke. [WATCH TIME: 5 minutes]

Using Veterans Health Data to Gain Insights on Sex Differences in Migraine and Stroke Risk: Elizabeth Seng, PhD

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings presented at AHS 2025 from a post hoc analysis of the phase 3b DELIVER study testing eptinezumab in patients with migraine. [WATCH TIME: 5 minutes]

Assessing Eptinezumab’s Impact in Reducing Migraine Burden Through Longer Interictal Periods: Amaal Starling, MD, FAHS, FAAN

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Slideshows

A summary of cutting-edge technology, including the world’s smallest fully implantable spinal cord neurostimulator for the treatment of chronic pain.

Clinical

New Neurosurgery Tech of Interest to Neurologists

New Neurosurgery Tech of Interest to Neurologists

Newsletter